Clinical Trials Logo

Hearing Loss, Bilateral clinical trials

View clinical trials related to Hearing Loss, Bilateral.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06424262 Not yet recruiting - Clinical trials for Hearing Loss, Sensorineural

Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

DETECT
Start date: June 2024
Phase: N/A
Study type: Interventional

This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.

NCT ID: NCT06354010 Not yet recruiting - Clinical trials for Sensorineural Hearing Loss, Bilateral

Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

SONG
Start date: May 2024
Phase:
Study type: Observational

The purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on GJB2 gene.

NCT ID: NCT06293482 Not yet recruiting - Clinical trials for Hearing Loss, Sensorineural

Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population

ACE
Start date: July 2024
Phase: N/A
Study type: Interventional

This study aims to evaluate the safety and efficacy of cochlear implantation for adults with bilateral sensorineural hearing loss who currently do not meet the FDA-approved indications for cochlear implantation. Following cochlear implantation, participants will complete speech perception assessments and questionnaires over the course of seven visits.

NCT ID: NCT05154188 Not yet recruiting - Clinical trials for Sensorineural Hearing Loss, Bilateral

Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users

PACIFIC
Start date: September 1, 2025
Phase:
Study type: Observational

On June 23, 2021, the Oticon Medical Neuro Cochlear Implant System (NCIS) was granted premarket approval (PMA) in the US to treat individuals 18 years or older, with bilateral severe-to-profound sensorineural hearing loss, who obtain limited benefit from appropriately fitted hearing aid(s). To help assure the continued safety and effectiveness of an approved device, a post-approval study was required as a condition of approval under 21 CFR 814.82(a)(2). The purpose of this study is to provide longer-term data on the safety and effectiveness of the Neuro Cochlear Implant System under general conditions of use in the postmarket environment.

NCT ID: NCT02545569 Not yet recruiting - Clinical trials for Hearing Loss, Bilateral or Unilateral

Evaluation of New Custom Made Hearing Product Technology and Shell Modification

CPS
Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The purpose of this evaluation is to receive the greatest benefit of new custom made hearing product technology and shell modification for the end customer and to continual improve the custom made hearing products.

NCT ID: NCT01529333 Not yet recruiting - Clinical trials for Mixed Conductive and Sensorineural Hearing Loss, Bilateral

Middle-Ear Implant With MET V Transducer (Aka MET V System)

Start date: May 2012
Phase: N/A
Study type: Interventional

The purpose and objective of this study is to evaluate the safety and efficacy of the MET V System for the treatment of individuals with mixed hearing loss.